Weill Cornell Medical College / NY Presbyterian
New York, 10065, United States
Location status: Recruiting
Location contact
Ananda Kimm-Drapeau
CONTACT
Thangamani Muthukumar, M.D.
CONTACT
Thangamani Muthukumar, M.D.
PRINCIPAL_INVESTIGATOR
NCT Number: NCT05711446
Urinary tract infections (UTI) are common in kidney transplant recipients and are an important cause of illness and hospital admissions. Past studies have shown that about 1 out of 5 of newly transplanted patients develop UTI within their first 3 months of transplantation. Such UTIs increase the risk for blood stream infection and acute rejection of the kidney, Improvements in urinary voiding techniques may reduce the frequency of UTI. The purpose of this study is to evaluate the benefits of "double voiding" in kidney transplant recipients.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
New York, 10065, United States
Location status: Recruiting
Ananda Kimm-Drapeau
CONTACT
Thangamani Muthukumar, M.D.
CONTACT
Thangamani Muthukumar, M.D.
PRINCIPAL_INVESTIGATOR
Urinary tract infections are common in kidney transplant recipients and are an important cause of morbidity and hospital readmissions. Several risk factors for UTI, both modifiable and unmodifiable, have been described in the literature. In normal (non-transplant) individuals, because of the anatomy of the ureter insertion into the bladder that creates a valve-like effect during voiding, reflux of urine into the kidney is prevented . However, after kidney transplantation, urine refluxing into the transplanted kidney is common. Depending on the surgical technique used for connecting the transplant ureter to the urinary bladder, reflux may occur in up to 79% of kidney transplant recipients. In addition, the routine usage of ureteral stents (double J stents) for the first 4-6 weeks after transplantation results in reflux. Vesicoureteral reflux increases the risk of UTI Double voiding, a process of passing urine more than once each time, is a technique that may assist the bladder to empty more effectively when urine is left in the bladder. By reducing the amount of left-over urine in the bladder after each void, double voiding may help reduce the incidence of UTI in kidney transplant recipients.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participant will be instructed to void twice.
Participant will void as usual
Time frame: First 3 months of transplantation
UTI will be defined as a clean catch urine bacterial culture that is reported as anything other than "<1000 CFU/ml (Colony Forming Unit / Milliliter)- Negative". Clean catch urine cultures are done at each follow-up visit as a standard of care, irrespective of patient symptoms. Hence the outcome will include both asymptomatic and symptomatic UTIs.
Time frame: First 3 months of transplantation
Time will be measured in days
Time frame: First 3 months of transplantation
Time frame: First 3 months of transplantation
Time frame: First 3 months of transplantation
Time frame: First 3 months of transplantation
Contact information is provided by the study sponsor or research team.
Ananda Kimm-Drapeau
CONTACT
Muthukumar Thangamani, M.D.
CONTACT
Weill Medical College of Cornell University
Other
A Randomized Trial of Double Voiding Versus Usual Voiding to Reduce the Incidence of Urinary Tract Infections in Kidney Transplant Recipients
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04815954
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Warsaw, Poland
View Trial DetailsNCT06976125
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Cleveland, Ohio, United States
View Trial DetailsNCT07559318
Antiobiotic Stewardship, Communicable Diseases
Melun, France
View Trial DetailsNCT07435844
Calcinosis, Calcium Metabolism Disorders
Mariánské Lázně, Carlsbad Region, Czechia
View Trial Details